Ann: Appendix 4E and Annual Report, page-24

Based on Phase 1b data, Azer-cel demonstrated high overall response rates (ORR) and molecular remissions in this challenging patient population. Specifically, the data revealed an ORR of 83% in patients who had relapsed after autologous CAR T therapy, with 61% achieving complete remission (CR). Additionally, in the most recent cohort receiving an optimized dose (Dose Level 4b), 60% achieved an ORR, and 66% of evaluable patients reached a full molecular remission (MRD-), which may predict the durability of the response. The treatment also showed an acceptable safety profile, with no occurrences of severe cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infection, or graft versus host disease in the most recent cohort

with above previous results just some predictions

1. High Overall Response Rate (ORR) and Complete Remission (CR):

   • In the earlier data, Azer-cel showed a strong ORR of 83% in patients who had relapsed after autologous CAR T therapy, with 61% achieving CR. If the treatment continues to perform similarly, we might expect the ORR and CR rates to remain high, particularly in the specific cohorts that have shown good response rates.

2. Optimized Dose Level Effectiveness:

   • The most recent cohort, which received the optimized Dose Level 4b, had an ORR of 60% and a molecular remission rate (MRD-) of 66%. This suggests that fine-tuning the dose level could enhance treatment effectiveness. Future results may show further improvements in ORR and CR as dosing and patient selection are refined.

3. Safety Profile:

   • The absence of severe side effects like CRS, ICANS, infections, or graft versus host disease in the recent cohort is a strong indicator of Azer-cel's safety. If the treatment maintains this safety profile, it will likely bolster confidence in the therapy's clinical viability and expand its use to more patients.
   • 
     

Predictions for Next Set of Results:

• Maintained or Improved Response Rates: We could anticipate that the next data set will show maintained or potentially improved ORR and CR rates, especially if the treatment protocol is further optimized and more patients are selected based on the favorable characteristics seen in responders.

• Further Validation of Safety: Continued absence of severe adverse events would confirm the acceptable safety profile of Azer-cel, making it more attractive for further development and potential regulatory approval.

• Longer Durability of Response: If patients continue to show durable responses (maintaining remission for six months or more), it would further validate the treatment's long-term efficacy, particularly in the challenging population of relapsed/refractory DLBCL.

• Potential Expansion of Indications: Positive results could also open up opportunities to explore Azer-cel in other CD19+ cancers or in combination with other therapies to enhance outcomes.

Overall, if the trends observed in the Phase 1b data continue, Azer-cel could establish itself as a highly effective and safe option for patients with relapsed/refractory DLBCL, leading to further clinical development and potential commercialization

Now for the share price prediction if above predictions holds good

If the clinical predictions hold true and Azer-cel continues to demonstrate strong efficacy and safety, Imugene's share price could see a significant increase. This rise would likely be driven by a combination of increased investor confidence, strategic partnerships, regulatory milestones, and market demand

particularly I am and I am sure even Imugene is targeting this, Monil might be getting big bucks to achieve this....

High Unmet Medical Need: Given the high unmet medical need in relapsed/refractory DLBCL patients, demonstrating a successful treatment could lead to high demand and, subsequently, high sales projections. This could raise analyst price targets for Imugene, resulting in a higher share price

Please DYOR this is just speculation...